AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Bleakley Financial Group LLC

Bleakley Financial Group LLC cut its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 7.9% in the 4th quarter, Holdings Channel reports. The firm owned 60,775 shares of the company’s stock after selling 5,200 shares during the period. Bleakley Financial Group LLC’s holdings in AstraZeneca were worth $3,982,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. boosted its position in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. Capital Performance Advisors LLP purchased a new stake in shares of AstraZeneca in the third quarter worth approximately $28,000. Albion Financial Group UT boosted its holdings in shares of AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after purchasing an additional 248 shares during the period. Groupama Asset Managment grew its position in AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after purchasing an additional 101,225 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in AstraZeneca in the 3rd quarter valued at approximately $45,000. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Up 2.0 %

AZN stock opened at $72.36 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The firm has a market cap of $224.39 billion, a PE ratio of 34.62, a PEG ratio of 1.18 and a beta of 0.46. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The company has a fifty day simple moving average of $67.27 and a 200 day simple moving average of $73.70.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. Sell-side analysts anticipate that AstraZeneca PLC will post 4.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.